Sign in or create an account to add this stock to your watchlist.
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone203-448-4600
Debt
Debt-to-Equity Ratio1.22
Current Ratio1.16
Quick Ratio1.16
Price-To-Earnings
Trailing P/E Ratio23.51
Forward P/E Ratio20.25
P/E Growth1.71
Sales & Book Value
Annual Sales$9.74 billion
Price / Sales2.18
Cash Flow$9.7935 per share
Price / Cash10.46
Book Value$40.81 per share
Price / Book2.51
Profitability
EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.07%
Return on Equity13.35%
Return on Assets4.75%
Miscellaneous
Employees55,000
Outstanding Shares207,140,000
IQVIA (NYSE:IQV) Frequently Asked Questions
What is IQVIA's stock symbol?
IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were IQVIA's earnings last quarter?
IQVIA (NYSE:IQV) posted its earnings results on Wednesday, May, 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.27 by $0.07. The medical research company had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.42 billion. IQVIA had a return on equity of 13.35% and a net margin of 13.07%. The firm's revenue was up 34.1% compared to the same quarter last year. View IQVIA's Earnings History.
When is IQVIA's next earnings date?
What guidance has IQVIA issued on next quarter's earnings?
IQVIA updated its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.IQVIA also updated its Q2 guidance to $1.17-1.24 EPS.
What price target have analysts set for IQV?
17 analysts have issued 1-year target prices for IQVIA's stock. Their predictions range from $93.42 to $128.00. On average, they expect IQVIA's share price to reach $110.3776 in the next year. View Analyst Ratings for IQVIA.
Who are some of IQVIA's key competitors?
Some companies that are related to IQVIA include Incyte (INCY), ICON (ICLR), EXACT Sciences (EXAS), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
Who are IQVIA's key executives?
IQVIA's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
- Mr. James H. Erlinger III, Consultant (Age 60)
Has IQVIA been receiving favorable news coverage?
News stories about IQV stock have trended positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. IQVIA earned a media sentiment score of 0.40 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 47.09 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are IQVIA's major shareholders?
IQVIA's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.63%), Farallon Capital Management LLC (1.52%), Northern Trust Corp (0.85%), Dimensional Fund Advisors LP (0.58%), Legal & General Group Plc (0.34%) and Schwab Charles Investment Management Inc. (0.28%). Company insiders that own IQVIA stock include Ari Bousbib, Corp 3I, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Kevin K Gordon, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for IQVIA.
Which major investors are selling IQVIA stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Sei Investments Co., Swiss National Bank, Guggenheim Capital LLC, The Manufacturers Life Insurance Company , Van ECK Associates Corp, Employees Retirement System of Texas and Northern Trust Corp. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for IQVIA.
Which major investors are buying IQVIA stock?
IQV stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Eagle Asset Management Inc., MD Sass Investors Services Inc., Carillon Tower Advisers Inc., Mackay Shields LLC, Farallon Capital Management LLC, Chilton Investment Co. LLC and Bloom Tree Partners LLC. View Insider Buying and Selling for IQVIA.
How do I buy shares of IQVIA?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IQVIA's stock price today?
One share of IQV stock can currently be purchased for approximately $102.54.
How big of a company is IQVIA?
IQVIA has a market capitalization of $21.17 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. IQVIA employs 55,000 workers across the globe.
How can I contact IQVIA?
IQVIA's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]
MarketBeat Community Rating for IQVIA (IQV)
MarketBeat's community ratings are surveys of what our community members think about IQVIA and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
IQVIA (NYSE:IQV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
18 Wall Street analysts have issued ratings and price targets for IQVIA in the last 12 months. Their average twelve-month price target is $110.3776, suggesting that the stock has a possible upside of 7.75%. The high price target for IQV is $128.00 and the low price target for IQV is $93.42. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.59 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $110.3776 | $110.3776 | $109.9071 | $102.1622 |
| Price Target Upside: | 7.75% upside | 14.83% upside | 8.21% upside | 1.81% downside |
IQVIA (NYSE:IQV) Consensus Price Target History
IQVIA (NYSE:IQV) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
IQVIA (NYSE:IQV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IQVIA (NYSE IQV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 92.12%
IQVIA (NYSE IQV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Michael J Evanisko | Director | Sell | 815 | $100.00 | $81,500.00 | |  |
| 3/15/2018 | Robert Parks | Insider | Sell | 896 | $105.73 | $94,734.08 | | |
| 3/5/2018 | Michael J Evanisko | Director | Sell | 816 | $100.00 | $81,600.00 | | |
| 2/26/2018 | James H Erlinger III | Insider | Sell | 10,000 | $100.00 | $1,000,000.00 | | |
| 1/17/2018 | James H Erlinger III | Insider | Sell | 10,000 | $99.97 | $999,700.00 | | |
| 12/20/2017 | James H Erlinger III | Insider | Sell | 10,000 | $101.21 | $1,012,100.00 | | |
| 12/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $101.79 | $4,690,483.20 | | |
| 11/30/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 7,497,807 | $102.00 | $764,776,314.00 | | |
| 11/30/2017 | John Connaughton | Director | Sell | 1,163,191 | $102.00 | $118,645,482.00 | | |
| 11/6/2017 | Jack M Greenberg | Director | Sell | 33,400 | $108.07 | $3,609,538.00 | | |
| 11/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $108.14 | $4,983,091.20 | 1,036,839 | |
| 10/18/2017 | James H Erlinger III | Insider | Sell | 10,000 | $100.51 | $1,005,100.00 | 27,340 | |
| 10/2/2017 | Ari Bousbib | Insider | Sell | 46,080 | $94.91 | $4,373,452.80 | 1,036,839 | |
| 9/27/2017 | James H Erlinger III | Insider | Sell | 10,000 | $94.52 | $945,200.00 | 27,340 | |
| 9/19/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 6,748,026 | $94.87 | $640,185,226.62 | | |
| 9/19/2017 | John Connaughton | Director | Sell | 1,030,429 | $94.87 | $97,756,799.23 | | |
| 9/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $95.65 | $4,407,552.00 | 1,036,839 | |
| 8/28/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 5,218,245 | $97.33 | $507,891,785.85 | | |
| 8/28/2017 | Dennis B Ph D Gillings | Director | Sell | 968,023 | $97.33 | $94,217,678.59 | 9,071,839 | |
| 8/25/2017 | Kevin C Knightly | Insider | Sell | 19,339 | $99.51 | $1,924,423.89 | 40,650 | |
| 8/9/2017 | Kevin C Knightly | Insider | Sell | 20,000 | $90.28 | $1,805,600.00 | 46,826 | |
| 8/7/2017 | Ari Bousbib | Insider | Sell | 92,160 | $90.35 | $8,326,656.00 | 1,082,919 | |
| 5/31/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 7,131,165 | $84.01 | $599,089,171.65 | | |
| 5/31/2017 | Dennis B Ph D Gillings | Director | Sell | 860,000 | $84.01 | $72,248,600.00 | 10,002,230 | |
| 5/30/2017 | John G Danhakl | Director | Sell | 761,143 | $84.01 | $63,943,623.43 | | |
| 5/17/2017 | Jack M Greenberg | Director | Sell | 6,092 | $82.50 | $502,590.00 | 2,930 | |
| 11/21/2016 | Jack M Greenberg | Director | Sell | 2,000 | $79.77 | $159,540.00 | 2,930 | |
| 6/9/2016 | Kevin K Gordon | COO | Sell | 24,000 | $66.41 | $1,593,840.00 | 41,899 | |
| 6/7/2016 | Corp 3I | Major Shareholder | Sell | 2,250,000 | $66.10 | $148,725,000.00 | | |
| 5/12/2016 | Annie H Lo | Director | Buy | 502 | $64.80 | $32,529.60 | 2,062 | |
| 5/10/2016 | Kevin K Gordon | COO | Sell | 24,000 | $67.42 | $1,618,080.00 | 41,899 | |
| 4/12/2016 | Kevin K Gordon | COO | Sell | 24,000 | $69.44 | $1,666,560.00 | 41,899 | |
| 3/22/2016 | Kevin K Gordon | COO | Sell | 3,639 | $65.01 | $236,571.39 | 21,538 | |
| 3/18/2016 | Kevin K Gordon | COO | Sell | 20,361 | $65.01 | $1,323,668.61 | 19,950 | |
| 3/1/2016 | Kevin K. Gordon | COO | Sell | 24,000 | $65.03 | $1,560,720.00 | 41,899 | |
| 9/2/2015 | Charles Edward Williams | SVP | Sell | 5,000 | $72.43 | $362,150.00 | 2,071 | |
| 5/19/2015 | Dennis B Ph D Gillings | Major Shareholder | Sell | 2,503,123 | $64.85 | $162,327,526.55 | | |
| 5/19/2015 | Tpg Advisors V, Inc. | Insider | Sell | 2,251,719 | $64.85 | $146,023,977.15 | | |
| 3/25/2015 | Michael J Evanisko | Director | Sell | 2,500 | $67.10 | $167,750.00 | | |
| 2/2/2015 | Kevin K Gordon | CFO | Sell | 25,000 | $60.19 | $1,504,750.00 | | |
| 1/7/2015 | Michael J Evanisko | Director | Sell | 2,500 | $57.86 | $144,650.00 | | |
| 1/2/2015 | Kevin K Gordon | CFO | Sell | 25,000 | $59.16 | $1,479,000.00 | | |
| 12/11/2014 | Jack M Greenberg | Director | Sell | 23,508 | $57.29 | $1,346,773.32 | | |
| 12/1/2014 | Kevin K Gordon | CFO | Sell | 25,000 | $56.77 | $1,419,250.00 | | |
| 11/10/2014 | Dennis B Ph D Gillings | Major Shareholder | Sell | 3,566,187 | $58.09 | $207,159,802.83 | | |
| 11/7/2014 | Michael J Evanisko | Director | Sell | 2,500 | $57.50 | $143,750.00 | | |
| 11/3/2014 | Kevin K Gordon | CFO | Sell | 25,000 | $59.00 | $1,475,000.00 | | |
| 7/2/2014 | Michael J Evanisko | Director | Sell | 5,000 | $54.00 | $270,000.00 | | |
| 5/27/2014 | Tpg Advisors Iii, Inc. | Major Shareholder | Sell | 3,287,209 | $50.23 | $165,116,508.07 | | |
| 3/26/2014 | Christopher Gordon | Director | Sell | 570,682 | $50.31 | $28,711,011.42 | | |
| 3/26/2014 | Dennis Ph Gillings | major shareholder | Sell | 570,681 | $50.31 | $28,710,961.11 | 16,609,827 | |
| 3/18/2014 | Mireille Phd Gillings | Director | Sell | 3,304,542 | $50.31 | $166,251,508.02 | | |
| 3/18/2014 | Tpg Advisors Iii, Inc. | major shareholder | Sell | 3,564,119 | $50.31 | $179,310,826.89 | | |
| 1/17/2014 | Derek Winstanly | VP | Sell | 60,000 | $50.00 | $3,000,000.00 | 229,500 | |
| 1/16/2014 | Michael Evanisko | Director | Sell | 5,000 | $50.00 | $250,000.00 | 15,400 | |
| 1/10/2014 | Derek Winstanly | VP | Sell | 60,000 | $48.00 | $2,880,000.00 | 229,500 | |
| 12/20/2013 | Derek Winstanly | VP | Sell | 60,000 | $46.00 | $2,760,000.00 | 229,500 | |
| 12/10/2013 | Derek Winstanly | VP | Sell | 60,000 | $44.00 | $2,640,000.00 | 229,500 | |
| 11/20/2013 | Michael Evanisko | Director | Sell | 8,000 | $43.00 | $344,000.00 | 20,400 | |
| 11/18/2013 | John Ratliff | COO | Sell | 212,140 | $42.55 | $9,026,557.00 | | |
| 11/18/2013 | Michael Mortimer | VP | Sell | 200,000 | $42.55 | $8,510,000.00 | 25,000 | |
| 5/14/2013 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 3,944,899 | $37.80 | $149,117,182.20 | | |
| 5/14/2013 | Mireille Gillings | Director | Sell | 2,257,805 | $37.80 | $85,345,029.00 | | |
(Data available from 1/1/2013 forward)
IQVIA (NYSE IQV) News Headlines
| Source: |
|
IQVIA (NYSE:IQV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IQVIA (NYSE:IQV) Income Statement, Balance Sheet and Cash Flow Statement
IQVIA (NYSE IQV) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
